Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
TAIPEI, Taiwan, Nov. 09, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has held an extraordinary general meeting and announced results of stockholder elections for the company’s 2017 Board of Directors. Dr. Guoliang Yu was re-elected as Chairman of the Board.
The elected Board of Directors comprise global experts and industry leaders from venture capital, corporate management, biotechnology and corporate governance. The complete list of elected directors is as follows:
Dr. Guoliang Yu, Director, Chairman of Board, re-elected
Mr. Sandy Chau, Director, re-elected
Mr. Chen-Chi Kai, Director, re-elected
Dr. Hongbo Lu, Director, re-elected
Dr. Jo Shen, Independent Director, re-elected
Dr. George Lee, Independent Director, re-elected
Mr. Wu-Fu Chen, Director, newly-elected
Mr. Andrew Lin, Independent Director, newly-elected
Dr. Jean-Pierre Wery, Director, newly-elected
The newly elected Director Mr. Wu-Fu Chen received his Master of Electrical Engineering degree from University of Florida and later completed his Ph.D. in Computer Science at University of California, Berkeley. He began his entrepreneur journey from Silicon Valley and was named “The Top 10 Entrepreneur of 2000”, “The Germinator”, and “The Top 100 Venture Investors in the US of 2002”. Mr. Wu currently served as the Chairman of Acorn Venture Capitals and is well known for his success in capital investments.
The newly elected Director Mr. Andrew Lin received his MBA degree from the University of Chicago and later completed a Master of Electrical and Computer Engineering degree at Massachusetts Institution of Technology. He is well recognized for his professional expertise in securities studies, investment banking, corporate management, and strategy consulting. Mr. Lin currently serves as the Chairman of Lotus Pharmaceutical and Independent Director of Fubon Life Insurance.
The newly elected Director Dr. Jean-Pierre Wery, is CEO of Crown Bioscience. Dr. Wery has been working for the company since 2008 and was appointed as CEO in 2016. He received his Ph.D. in Physics at Université de Liège and completed his postdoctoral studies at Purdue University.
The elected Board will serve a three year term. The three Independent Directors Jo Shen, George Lee, and Chun Lin will serve as the members of Audit and Compensation Committees. The shareholder voting participating rate is close to 70% and the major shareholders include OrbiMed Healthcare Fund Management, Lilly Asia Ventures, and Center Laboratories.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
